Results of the October 2014 Innovation Grants competition

We are pleased to announce the results of the most recent Innovation Grants competition to support unique and creative research ideas that will impact cancer. Below is a listing of newly awarded Canadian Cancer Society (CCS) Innovation Grants.

Out of a total of 271 grant applications, 34 Canadian Cancer Society Innovation Grants have been approved – a 13% success rate. All grants have been awarded to a maximum budget of $200,000 with a maximum 3 year term. The 34 grants total over $6.7 million in funding over the terms of these grants.

We are also very pleased that all grants are being funded to their full panel recommended amounts and that no administrative decrements are being applied.

Funds committed to this competition have been made possible by the significant efforts of Canadian Cancer Society volunteers and donors across the country. 

Summaries of awarded grants

Please note:
  • Amounts listed below represent the total dollars awarded by grant year and may include funds for salaries, supplies, and/or equipment.
  • The start date for these grants is February 1, 2015.
  • Only the Principal Investigator is named in this listing. Co-Principal Investigators, Co-Applicants and/or Additional Authors may also be associated with these grants.
Note Carefully:

Although every effort has been made to ensure the accuracy of the listing below, this list does not constitute an "official" notification.

Successful applicants will be informed, in writing, with an official Notification of Award giving the details pertaining to their grant. 

Applicant
Institution
Title
Award
Ailles, Laurie
Ontario Cancer Institute/PMCC - UHN
Identification and characterization of tumour-initiating cells in clear cell renal cell carcinoma
2015/2016 :  $91,600
2016/2017 :  $99,600
Allen-Vercoe, Emma
University of Guelph
Determining the virulence determinants of fusobacterium nucleatum to define diagnostic and therapeutic targets for colorectal cancer
2015/2016 :  $99,987
2016/2017 :  $99,988
Archambault, Vincent
University of Montreal
A novel strategy for the development of Polo-like kinase 1 inhibitors
2015/2016 :  $100,000
2016/2017 :  $100,000
Autexier, Chantal
Lady Davis Institute (affil. McGill)
A haploid genetic screen in human cells to identify genes regulating chromosome end protection
2015/2016 :  $100,000
2016/2017 :  $100,000
Brooks-Wilson, Angela
BC Cancer Agency (Vancouver)
Genetic resistance to cancer
2015/2016 :  $99,934
2016/2017 :  $99,800
De Carvalho, Daniel
Ontario Cancer Institute/PMCC - UHN
CIMP (the CpG island methylator phenotype) as a molecular marker for EZH2 inhibitor therapy: biological and molecular mechanisms
2015/2016 :  $100,000
2016/2017 :  $100,000
Draper, Jonathan
McMaster University
Modelling lung cancer using human lung organoids
2015/2016 :  $93,232
2016/2017 :  $100,000
Forman-Kay, Julie
The Hospital for Sick Children
Modulating disordered protein phase separation to discover novel therapeutic agents for ewing sarcoma and other cancers
2015/2016 :  $99,725
2016/2017 :  $99,675
Gleason, James
McGill University
Hybrid antiandrogen / HDACi drugs for prostate cancer
2015/2016 :  $60,000
2016/2017 :  $73,000
2017/2018 :  $67,000
Goldenberg, Anna
The Hospital for Sick Children
Improving drug response prediction in non-small cell lung cancer
2015/2016 :  $80,345
2016/2017 :  $73,615
2017/2018 :  $45,855
Hirst, Martin
University of British Columbia
Reversing epigenetic defects in leukemia
*Co-funded by the Lotte and John Hecht Memorial Foundation
2015/2016 :  $99,000
2016/2017 :  $100,000
Holt, Rob
BC Cancer Agency (Vancouver)
Arming lymphocytes to kill apoptosis resistant cancer cells
2015/2016 :  $65,535
2016/2017 :  $69,535
2017/2018 :  $64,532
Huntsman, David
BC Cancer Agency (Vancouver)
Targeting the epigenome in cancers with SMARCA4 and SMARCA2 dual deficiency
2015/2016 :  $100,000
2016/2017 :  $100,000
Johnson, Nathalie
Lady Davis Institute (affil. McGill)
Optimizing therapy for STAT6-mutant DLBCL
2015/2016 :  $99,800
2016/2017 :  $99,800
Karp, Igor
Western University
Novel hypoglycemic agents and cancer risk
2015/2016 :  $100,000
2016/2017 :  $94,405
Keating, Armand
Ontario Cancer Institute/PMCC - UHN
NK cell line therapy of metastatic ovarian cancer
2015/2016 :  $99,750
2016/2017 :  $99,750
Kongkham, Paul
The Toronto Hospital (Western Division) - UHN
Genome-wide profiling of DNA cytosine methylation and hydroxymethylation patterns contributing to normal astrocyte differentiation and gliomagenesis
2015/2016 :  $100,000
2016/2017 :  $94,790
Koritzinsky, Marianne
Ontario Cancer Institute/PMCC - UHN
Regulation of extracellular protein expression in hypoxia through ER-localized protein folding
2015/2016 :  $100,000
2016/2017 :  $100,000
Kwok, Benjamin
University of Montreal
Targeting the oncogenic kinesin motor protein KIF14 for cancer therapy
2015/2016 :  $100,000
2016/2017 :  $100,000
Lee, Patrick
Dalhousie University
Temporospatial onco-viro-Immunome analysis for deciphering, therapeutic targeting and strategic management of the immunological determinants of virus-assisted anti-cancer immunotherapy
2015/2016 :  $100,000
2016/2017 :  $100,000
Mahoney, Douglas
University of Calgary
Understanding oncolytic virus delivery using intravital imaging
2015/2016 :  $100,000
2016/2017 :  $100,000
McIntosh, Lawrence
University of British Columbia
Inhibitors of SAM domain polymerization as a novel therapy to target ETV6 chimeric oncoproteins
2015/2016 :  $100,000
2016/2017 :  $100,000
Meloche, Sylvain
University of Montreal
Development of first-in-class small molecule inhibitors of a cancer-related ubiquitin-conjugating enzyme
2015/2016 :  $100,000
2016/2017 :  $100,000
Moon, Nam Sung
McGill University
Identification of the metabolic pathways that affect the proliferation and survival of RB-deficient cells
2015/2016 :  $66,660
2016/2017 :  $66,660
2017/2018 :  $66,660
Mueller, Christopher
Queen's University
Towards a universal blood test for cancer
2015/2016 :  $100,000
2016/2017 :  $100,000
Nelson, Brad
BC Cancer Agency (Victoria)
Oncolytic viruses as beacons to enable tumour-selective targeting of antibody-based therapeutics
2015/2016 :  $100,000
2016/2017 :  $100,000
Pantopoulos, Konstantinos
Lady Davis Institute (affil. McGill)
Targeting cancer by small molecule inhibitors of iron regulatory protein 2 (IRP2)
2015/2016 :  $100,000
2016/2017 :  $100,000
Perrin, David
University of British Columbia
Synthetic amanitin analogs as new leads for bioreductive and targeted therapies
2015/2016 :  $95,900
2016/2017 :  $97,000
2017/2018 :  $2,000
Rousseau, Marie-Claude
Institut national de la recherche scientifique
Impact of bacillus calmette-guerin (BCG) vaccination on the risk of lymphoma
2015/2016 :  $72,606
2016/2017 :  $75,551
2017/2018 :  $49,187
Scott, David
BC Cancer Research Centre
Discovery and implementation of biomarkers for central nervous system relapse in diffuse large B-cell lymphoma
2015/2016 :  $96,381
2016/2017 :  $55,503
2017/2018 :  $47,903
Selby, Peter
Centre for Addiction and Mental Health
Personalized patient alerts and care pathways to prompt prevention interventions for combined alcohol and tobacco users in primary care
2015/2016 :  $99,975
2016/2017 :  $99,925
Stirling, Peter
BC Cancer Agency (Vancouver)
DNA:RNA hybrids as a mechanism of genome instability in cancer
2015/2016 :  $100,000
2016/2017 :  $100,000
Uniacke, Jim
University of Guelph
Investigating cis-regulagtory RNA elements as a tool to express therapeutic RNAs in hypoxic tumours
2015/2016 :  $100,000
2016/2017 :  $100,000
Wing, Simon
The Research Institute of the McGill University Health Centre (RI-MUHC)
Identifying novel therapeutics for prevention and treatment of cancer cachexia
2015/2016 :  $94,617
2016/2017 :  $50,521
2017/2018 :  $54,851

Last modified on: January 30, 2017